O’Donnell School of Public Health researchers use AI to seek new lung cancer treatments

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

October 02, 2026

Vol.52 No.36

Perspective

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

NCI launches AI tool to help match patients to clinical trials

NCI Director Anthony Letai announced the development of TrialMatch, an AI tool that helps oncologists identify clinical trials for their patients.

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

In Brief

UNC researchers receive $40M grant to use AI to help develop cancer vaccines

UNC Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation, the non-profit parent organization that governs the for-profit company OpenAI Group PBC, to generate data that could make personalized cancer vaccines more effective.

September 18, 2026

Vol.52 No.34

Clinical Roundup

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

September 18, 2026

Vol.52 No.34

O’Donnell School of Public Health researchers use AI to seek new lung cancer treatments

YOU MAY BE INTERESTED IN

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

NCI launches AI tool to help match patients to clinical trials

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

UNC researchers receive $40M grant to use AI to help develop cancer vaccines

EGFR mutation linked to dramatically increased lung cancer risk

Renew today!

Subscriber content

Never miss an issue!

Login